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Cannabinoids Induce Immunoglobulin Class Switching to IgE in B Lymphocytes 
 
Marisela Agudelo 
 
ABSTRACT 
 
Cannabinoid treatment increases Th2 activity and previous reports showed B cells 
express the highest level of CB2 mRNA relative to other immune cells suggesting that 
cannabinoids play a critical role in B cell activation and maturation. To examine the 
direct effect of cannabinoids on B cell antibody class switching, mouse splenic B cells 
were purified by negative selection and cultured with IL4 and anti-CD40 in the presence 
or absence of the nonselective cannabinoid agonist, CP55940, or the CB1 selective 
agonist, methanandamide, or the CB2 selective agonist, JW015.  The cultures were then 
analyzed at different times by flow cytometry for expression of B cell surface markers, 
such as CD19, CD138, CD40, MHCII, CD23, CD80, CD45R, immunoglobulins 
produced such as IgM, IgE, IgD, and IgG1, and Toll-like receptors such as TLR 2 and 4.  
Cells treated with CP55940 showed an increase in surface expression of IgE by day 5 in 
culture; methanandamide had no effect. CP55940 also induced an increase in secreted 
IgE in culture supernatants analyzed by ELISA. In addition, CB2 receptors were 
increased on B cells following stimulation with IL-4 and anti-CD40 and the class 
 ix
switching effect of CP55940 was attenuated by the CB2 antagonist, SR144528.   
We also observed that cannabinoid treatment of B cells modulates cell functions 
other than antibody class switching such as surface marker and TLR expression. 
CP55940 caused a significant increase in surface expression of TLR 4, but had no effect 
on other markers. Additional experiments with cannabinoid receptor selective agonists 
and antagonists suggested both CB1 and CB2 receptors were involved in the TLR effect.  
Receptor involvement and Gi coupling was supported by our findings that cannabinoids 
inhibit intracellular cAMP levels in forskolin stimulated B cells, and increasing 
intracellular cAMP with forskolin suppressed IgE antibody class switching in activated B 
cell cultures. These results suggest cannabinoids negatively regulate cAMP in B cells 
resulting in increased IgE. In conclusion, cannabinoids can directly affect the function of 
B cells by inducing antibody class switching to IgE and TLR4 expression through 
mechanisms involving CB1 and CB2 receptors suggesting the endocannabinoid system 
may be an important regulator of humoral immunity and the allergic response.  
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INTRODUCTION 
 
Cannabis and Cannabinoids 
 
Cannabis is one of the oldest psychotropic drugs known to humanity (1). It has 
been used in China since the Neolithic period, around 4000 BC (41). Even though 
cannabis has been widely known and used for centuries, it was not until the end of the 
19th century that the psychoactive chemicals in marijuana began to be defined and 
purified.  This started with the isolation of cannabinol from a red oil extract of cannabis. 
It’s chemical structure was elucidated in the early 1930s by R.S. Cahn, and its synthesis 
first achieved in 1940 in the laboratories of R. Adams in the U.S.A. and Lord Todd in the 
U.K (55). Cannabis sativa contains more than 460 known chemicals and over 60 
cannabinoid alkaloids (1); however, the main psychoactive component is ∆9-
tetrahydrocannabinol, commonly known as THC,  the structure and purification of which 
was accomplished in Raphael Mechoulam's laboratory in 1964 (55). 
 
Cannabinoids and Medicine 
 
Cannabis use is widely known to offer analgesic, appetite stimulant, antiemetic, 
muscle relaxant, and anticonvulsant benefit (1). According to the National Institute on 
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Drug Abuse, since 1970, marijuana has been classified as a Schedule I controlled 
substance. This means that the drug, at least in its smoked form, has no commonly 
accepted medical use. However, in spite of the controversies in the U.S, Marinol 
(Dronabinol), a synthetic version of THC, has been manufactured by Solvay 
Pharmaceuticals since the 1980s as an approved appetite stimulant for HIV/AIDS 
patients and as an antiemetic to alleviate the nausea and vomiting associated with cancer 
chemotherapy.  
To date, cannabinoid-based drugs are gaining political and public support to be 
used for the treatment of chronic diseases (31). GW Pharmaceuticals has undertaken a 
major research program in the United Kingdom to develop and market distinct cannabis-
based prescription medicines in a range of medical conditions. Their research includes 
investigations in the relief of pain in multiple sclerosis (MS), spinal cord injury, 
peripheral nerve injury, central nervous system damage, neuroinvasive cancer, cerebral 
vascular accident, as well as for the relief of pain and inflammation in rheumatoid 
arthritis. Along with these investigations, new and better methods for delivery of these 
compounds are being studied such as inhalation of THC aerosols (49) and therapeutic 
skin patch applications (64). Most recent clinical trials have also been conducted with 
preparations of Δ9-THC hemisuccinate administered in a rectal suppository, with inhaled 
cannabis and with cannabis extracts administered either in capsules (Cannador) or by a 
pump-action oromucosal spray (Sativex). The main cannabinoid constituents of both 
Cannador and Sativex are Δ9-THC and the non-psychoactive plant cannabinoid, 
cannabidiol (54). 
Even though the medicinal use of marijuana and other cannabinoids is gaining 
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worldwide support, a lot more research needs to be done on cannabinoids side effects and 
other potential medical uses. Therefore, understanding the effects of these drugs on the 
immune system is critical. 
 
Cannabinoid Receptors 
 
It is now recognized that the brain and immune system have a cannabinoid system 
of receptors and ligands called the endocannabinoid system. This system is composed of 
two receptors, CB1(39) and CB2 (47, 66), and endogenous ligands such as anandamide 
(8). CB1 receptors are concentrated in the brain and spinal cord, with some found in 
peripheral tissue. CB1 was first cloned from a rat brain cDNA library (39). Human CB1 
was first cloned in 1991, and encoded a protein with 472 amino acids (4). The mouse CB1 
sequence has also been cloned (7), and showed 99% and 97% identity to rat and human 
CB1, respectively, at the amino acid level (34). The CB2 receptors are largely present in 
the periphery, especially in immune cells. CB2 was cloned using polymerase chain 
reaction (PCR) from a human promyelocytic cell line (HL60) cDNA library (47). CB2 
cDNA was reported to encode a protein of only 360 amino acids and showed only a 44% 
identity with the human CB1 receptor. The mouse (65) and rat (3) CB2 genes have also 
been cloned and encode proteins of 347 and 410 amino acids, respectively. All these 
cloning studies suggested that cannabinoid receptors (CBRs) were displayed not only in 
brain, but also in the immune system. CBRs are members of the seven-transmembrane G 
protein-coupled receptor superfamily (25). CB2 is coupled predominantly through Gi/o 
proteins, i.e., negatively through the Gα subunit to adenylyl cyclase and positively 
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through Gβ/γ to MAP kinase.  Additionally, at least for CB1, there is some evidence that 
shows cannabinoid receptors may signal through Gs (55).  
 
Endocannabinoids and Synthetic Cannabinoids 
 
It has also been shown that the body naturally contains endogenous compounds. 
The first endogenous ligand described for cannabinoid receptors was anandamide (ANA), 
an arachidonylethanolamine. Anandamide was isolated from pig brain (8). A more stable 
anandamide analogue has also been synthesized, (R)-(+)-Methanandamide, known as a 
selective agonist for CB1. Other endocannabinoids have been isolated from tissues such 
as 2-arachidonylglycerol, or 2-AG  (42), and 2-arachidonylglyceryl ether, or 2-AGE (17). 
The discovery of these endogenous compounds has led to the idea that the cannabinoid 
receptors are part of an important physiological control system. This discovery has great 
implications for the potential of developing novel drugs that act at the cannabinoid 
receptors.  
Furthermore, research on the structure-activity relationship of THC led to the 
synthesis of non-classical cannabinoid analogues. Bicyclic analogs, such as CP55,940  
had been synthesized with affinity higher than THC. CP55,940 is a nonselective, high 
affinity ligand with potent biological effects that are mediated through binding both CB1 
and CB2 (43). Several synthetic selective agonists and antagonists of the CB1 and CB2 
receptors have already been developed. A number of CB2 selective agonists have been 
synthesized such as JWH015 (22) and HU308 (18). Highly selective antagonists for CB1 
(SR 141716A) (11); and CB2 (SR144528) have also been synthesized (61).  
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Table 1. Cannabinoid Receptor Ligands. Summary of the binding affinities (Ki values) 
and selectivity of cannabinoid receptor ligands used in our research studies (35, 38) 
 
 
 
 
 
 
 
 
 
Selectivity Compound CB1  Ki (nM) CB2  Ki (nM) 
nonselective ∆9THC 53.3 75.3 
nonselective CP55,940 1.3 1.3 
CB1 selective agonist Methanandamide 20 815 
CB2 selective agonist JWH015 
CB65 
383 
1000 
13.8 
3.3 
CB1 selective antagonist SR1 (SR 141716A) 11.8 13,200 
CB2 selective antagonist SR2 (SR 144528) 437 0.6 
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B Lymphocytes 
B cells are an essential component of the adaptive immune system and play the 
major role in the humoral immune response. The principal functions of B cells are to 
make antibodies against antigens, perform the role of Antigen Presenting Cells (APCs) 
and eventually develop into memory B cells after activation by antigen (60). Maturation 
of B cells begins in the bone marrow of mammals wherein pre B cells develop into 
immature and mature B cells expressing surface immunoglobulin (sIg) receptors for 
antigen. The mature B cell expresses both IgM and IgD forms of the receptor and these 
cells migrate to peripheral tissues where they are positioned to sense and respond to 
antigen (52). Once a B cell encounters its cognate antigen and receives additional signals 
from a T helper cell and other accessory cells, it can further differentiate into plasma cells 
or memory B cells (60). 
Purified B cells cultured in vitro need two major signals to survive and proliferate, 
e.g. stimulation with anti-CD40 and IL-4. Anti-CD40 (membrane contact signal) 
stimulates B cell activation and proliferation, while IL-4 (cytokine signal) enhances 
proliferation as well as antibody class switching to produce IgE rather than IgM. Recent 
reports showed that stimulation of primary B cells in vitro with IL4 and anti-CD40 can 
also induce a significant increase in syndecam-1/CD138 positive cells, driving B cell 
differentiation into highly antibody secreting plasma cells (6). CD138 (syndecam 1) is a 
proteoglycan that recognizes extracellular matrix and growth factors, appears during 
activation and differentiation of B cells, and is specific for the terminally differentiated B 
cell or plasma cell (71). 
 7
Effects of Cannabinoids on the Immune System 
 
There is much evidence that cannabinoids modulate immunity, and cannabinoid 
receptors and endogenous ligands have been reported to be produced by cells of the 
immune system and to regulate immune cell function with immune suppression being a 
dominant response (32, 33). In addition, cannabinoids have been reported to polarize 
toward Th2 (humoral) immunity in a variety of models and at least a portion of this effect 
is due to a modulation of T helper cytokines produced by dendritic cells, NK cells,  and T 
cells (37).   
 
Effects of Cannabinoids on B Lymphocytes 
 
THC has been reported to either suppress (27) or enhance (51) B cell functions 
such as antibody formation; however, these studies were done using mixed immune cell 
populations and therefore the direct effect of the drug on isolated B cells was not 
determined. Other studies have shown that B lymphocytes express an abundance of CB2 
message relative to other immune cells (5, 36) and cannabinoids have been shown to 
increase B cell function rather than suppress it.  For example, proliferation of B cells was 
reported to be increased by cannabinoid agonists (5), CB2 receptors were reported to be 
increased in B cells following IL-4 treatment (36), serum IgE levels were non-
specifically increased in 50% of marijuana smokers (59), and Th2-type antibody 
responses to Legionella pneumophila were increased in THC-treated and immune 
stimulated mice (51).  It is believed that CB2 plays a critical role in the activation of B 
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cells and in human tonsillar B cells, the level of CB2 mRNA was increased after 
activation with anti-CD40 antibody (5). Message was also increased in mouse 
splenocytes following activation (36). 
 
Cannabinoids and Class Switching 
 
This research project focuses on the effect of cannabinoids on B cell functions, 
specifically differentiation and antibody class switching in vitro. From basic 
immunology, it is known that both a membrane contact signal and cytokine signals are 
necessary to induce B-cell proliferation and differentiation. Therefore, to maintain 
isolated B cells in vitro, the cells are stimulated with anti-CD40 and IL-4. Anti-CD40 
(membrane contact signal) stimulates B cell activation and proliferation, while IL-4 
(cytokine signal) enhances proliferation as well as antibody class switching to IgE. Th2 
cytokines such as IL-4 stimulate B cells to undergo immunoglobulin (Ig) heavy chain 
class switching and thus induce these cells to produce IgE and IgG1 rather than IgM and 
IgG2a (69). Because we had observed that cannabinoids increased IgG1 and not IgG2a 
antibodies (51) and because IL-4 activity is reported to promote the expression of CB2 
mRNA in B cells (65) we examined the possibility that cannabinoids act on B cells 
directly to induce Ig class switching through a cannabinoid receptor mediated 
mechanism. 
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Cannabinoids and Toll-Like Receptors (TLRs)  
 
Toll-like receptors are a type of Pattern Recognition Receptor (PRR) that plays a 
key role in the innate immune system and also in the adaptive immune response by 
stimulating B cells. Most recent data show that TLRs control multiple cell functions and 
activate signals that are critically involved in the initiation of adaptive immune responses 
(24).  For example, signaling through TLR4 promotes B cell maturation (20), class switch 
recombination in early mouse B cells is mediated by Toll-like receptors (16), and TLR4 
surface expression on human B cells is modulated by IL-4 (45). Therefore, TLR4 must 
play an important role on B cell class switching.  
Furthermore, there is some evidence that the CB2 agonist, JWH-133, suppresses 
LPS-induced up-regulation of TLR4 and MyD88 (73), but these experiments were done 
in bone marrow derived dendritic cells.  Currently, there is no literature examining the 
effect of cannabinoids on TLR expression in B cells. Therefore, the role of cannabinoids 
on TLR expression and signaling on B cells still needs to be elucidated.   
 
Cannabinoid Receptor Mechanisms 
 
As previously described, it is well known that B cells from mouse and human 
express CB2 mRNA in abundance (5, 36), but  the role of cannabinoid receptors and 
mechanisms of action on B cell activation are unclear; therefore, studies using 
cannabinoid agonists and antagonists, and measuring cAMP accumulation in B cells will 
provide a better understanding of the role of these receptors in B cell proliferation and 
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class switching.  
As previously described, cannabinoid receptors are G protein-couple receptors 
and upon binding a cannabinoid ligand such as THC, these receptors associate with 
members of the Gi/o family of proteins.  The Gi/o is a heterotrimeric complex of 3 
proteins composed of the Gα and Gβ/γ subunits.  Upon activation by ligand binding, the G 
protein complex is activated releasing the Gα subunit that binds to and inhibits adenylyl 
cyclase.  The Gβ/γ dimer is also released and can activate adenylyl cyclase, 
phospholipase pathways, and the MAPK pathway (2).  Additionally, at least for CB1, 
there is some evidence cannabinoid receptors may also activate and signal through Gs 
proteins (55).  The pathways activated by G protein-coupled receptors are powerful 
signaling pathways which have been implicated in many cellular differentiation events 
including class switch recombination  and responses to cytokines (2) and these pathways 
have been reported to be activated by stimulation through cannabinoid receptors (21). 
Other studies show that STAT6 up regulates CB2 message expression and plays an 
important role in IL-4 -mediated B cell activation and differentiation (65). Therefore, 
measuring accumulation of cAMP and activation of these signaling pathways after 
cannabinoid treatment may lead to a better understanding of the mechanisms involved in 
the cannabinoid effects observed in B cells.   
 
Project Significance 
 
To date, the role of cannabinoids in regulating the immune system is still unclear. 
Therefore, examining the effects of cannabinoids on B lymphocytes will contribute to our 
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understanding of the advantages and disadvantages of the medical use of cannabinoid 
based drugs. Furthermore, cannabinoid receptor studies will provide the basis for future 
drug development, making a great contribution to the field of immune-mediated diseases. 
The current study examines a model of B cell class switching and the effects 
cannabinoids have in the regulation of B cell function. B cell class switching to IgE is a 
hallmark event in allergies and asthma, and the spreading epidemic of these diseases has 
increased the need for more research in this area.  
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OBJECTIVES 
 
It is well understood from previous literature and our own preliminary data that 
purified B cells treated with IL-4 and anti-CD40 proliferate and undergo class switching 
from IgM to IgE (19). However, the modulation by cannabinoids and their receptors in 
this class switching process has not been explored. The objective of this project is to get a 
better understanding of the role of cannabinoids and receptors on B cell function and 
antibody formation. It is hypothesized that B cell differentiation and class switching can 
be modulated by cannabinoids and cannabinoid receptors. In order to test this hypothesis, 
the following aims are proposed. 
 
Aim 1. To Determine the Extent of Cannabinoid Receptor 2 Expression in B Cell 
Activation 
 
Of all immune cells tested, B cells express the highest level of CB2 mRNA (36). It 
has been reported that CB2 receptor expression is up regulated during human tonsillar B 
cell activation through CD40 (5). Other studies indicated that the CB2 transcript was 2 
fold higher in abundance in murine B cells than in whole splenocyte preparations (36). In 
summary, data from previous studies have confirmed that the expression of CB2 mRNA 
is more abundant in B cells. However, there is no conclusive data on CB2 receptor 
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expression in B cells at the protein level. Therefore, it is necessary to analyze the 
expression of CB2 receptors at the protein level. Our own preliminary studies have shown 
that CB2 protein is more abundant on activated primary B cells cultured for five days 
with IL-4 and anti-CD40. Primary unstimulated B cells have very low CB2 levels.  
Furthermore, murine B cell line experiments have shown that CB2 levels are also 
abundant on a mature B cell line, K46u, and a pre-B cell line, 18.81 (unpublished 
observation). Therefore, it is proposed that CB2 receptors are highly expressed on 
activated B cells; and CB2 receptor expression will change as the activity of B cell 
changes. B cells will be activated with different activators such as anti-CD40 and 
recombinant IL-4, then CB2 mRNA and protein expression will be measured at different 
time points by RT-PCR and flow cytometry, respectively. It is hypothesized that CB2 
receptor expression will change as B cell activity, such as proliferation and class 
switching, changes. 
 
Aim 2. To Determine the Effects of Cannabinoids on B Cell Activation and Class 
Switching 
 
Previous studies have shown that IL-4 and CD40 ligand are sufficient to induce 
resting murine B cells to divide and switch antibody isotypes from IgM and IgD to IgG1 
and IgE (19). Anti-CD40, PMA, IFN-γ, and marijuana smoking have been shown to 
increase CB2 expression while LPS, and TGF-β have been shown to suppress CB2 
expression (35). Cannabinoids, independent of effects on helper T cells, may modulate 
antibody production by directly stimulating B cell proliferation and class switching in 
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combination with other B cell activating factors.  Splenic B cells, from C57BL/6 CB2 
wildtype and knockout mice, will be cultured for five days with IL-4 and anti-CD-40. 
Different time points and concentrations of ligands will be used in the presence or 
absence of cannabinoids such as CP55,940, methanandamide, JW015, and CB65. 
Furthermore, CB1 and CB2 antagonists will be also used to treat B cells in the presence of 
cannabinoids. The specific purpose of this aim will to determine the effects of 
cannabinoids, cannabinoid agonists, or antagonists in this in vitro class switching process. 
It is proposed that cannabinoids can induce an increase in IgE antibodies by direct action 
on B cells. Isotype switched B cells will be distinguished by analyzing IgE, IgG1, IgG2a 
IgA, IgD, and IgM positive and negative populations by flow cytometry. B cell activation 
will be assessed by analyzing B cell surface markers such as CD45, CD19, MHCII, 
CD80, CD23, and CD138. B cell proliferation will be measured with CyQUANT™ NF 
Cell Proliferation Assay Kit, and B cell counts with trypan blue.  It is hypothesized that 
cannabinoids can regulate B cell proliferation and class switching in a cannabinoid 
receptor dependent way.  
 
Aim 3. To Determine the Molecular Mechanisms Involved in Cannabinoid 
Regulation of B Cell Antibody Class Switching 
 
Different in vitro studies have shown that CD40L and IL-4 are sufficient to 
stimulate B cells to divide, class switch, and secrete antibodies (15, 19). It appears that 
anti-CD40 can stimulate B cell division while IL-4 enhances division as well as antibody 
class switching to IgE. Furthermore, cannabinoids may modulate this class switching 
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effect. Data from previous aims show CP55940 treatment significantly increased IgE 
surface expression and secretion. But, the mechanism is still unclear. Therefore, we 
propose to find the possible mechanisms involve in cannabinoid regulation of B cell class 
switching by examining cannabinoid receptors, G protein-coupled mechanisms, and toll 
like receptors.  
From previous literature, we know that cannabinoid receptors suppress adenylyl 
cyclase and cAMP through the activation of  Gi/o protein coupling (55). It is also well 
known that certain CB2 agonists are known to inhibit forskolin stimulation of cAMP 
(14). Forskolin is labdane diterpene produced by the Indian coleus plant (Plectranthus 
barbatus). It works by binding and activating the enzyme adenylyl cyclase, increasing 
intracellular levels of cAMP. Therefore, measuring cAMP levels after forskolin and 
cannabinoid treatment can be used to determine if cannabinoids are acting through Gi 
protein-coupled mechanisms. G protein-coupled mechanisms can mediate class switching 
as has been observed with other agents that increase cAMP (62). To examine the direct 
effect of CP55940 on B cell cAMP production, B cells will be pre-treated with IL-4 and 
anti-CD40 for 48 hours, harvested, and stimulated with Forskolin or CP55940 for 15 min. 
cAMP will be measured by luminescence. We will also determine if increasing 
intracellular cAMP by forskolin treatment of B cells can decrease the expression of IgE.  
It is hypothesized that cannabinoids induce B cell class switching through Gi protein-
coupled mechanisms involving CB1 and CB2 receptors; in addition, toll like receptors 
might also be involved in drug effects on antibody production.  
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MATERIALS AND METHODS 
 
Mice  
 
C57BL/6 mice, 6-12 weeks of age, were obtained from our CB2 breeding colony 
housed and cared for at the University of South Florida Health Science Center animal 
facility, which is fully accredited by the American Association for Accreditation of 
Laboratory Animal Care. Cannabinoid receptor gene deficient mice (CB2-/-) on the 
C57BL/6 background were bred by USF animal facility staff from stocks provided by Dr. 
Nancy Buckley (California State Polytechnic U.) 
 
Cannabinoid Drugs 
 
CP55940 [(-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl) phenyl]-trans-4-(3-
hydroxypropyl) cyclohexanol], (R)-(+)-Methanandamide [(R)-N-(2-Hydroxy-1-
methylethyl)-5Z,8Z,11Z,14Z-icosatetraenamide],  JWH 015 [2-Methyl-1-propyl-1H-
indol-3-yl)-1-naphthalenylmethano ne], and CB65  [N-Cyclohexyl-7-chloro-1-[2-(4-
morpholinyl)ethyl]quinoli n-4(1H)-one-3-carboxamide] were obtained from Tocris 
Bioscience, Ellisville, MO.  CP55940 is nonselective with Ki value for both CB1 and CB2 
of 1.3 nM.  Methanandamide is a CB1 selective agonist with Ki values for CB1 and CB2 
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of 20 nM and 815 nM, respectively. CB2 selective agonists are JWH 015 with Ki values 
of 383 and 13.8 nM for CB1 and CB2, respectively (35) and CB65 with Ki values of 1000 
nM and 3.3 nM for CB1 and CB2, respectively. CP55940 was first diluted in 95% ethanol 
to a concentration of 100 mM and then in 10% fetal calf serum-RPMI 1640 medium to a 
working concentration of 100 uM. Methanandamide was diluted in ethanol to a 
concentration of 5 mg/ml and then in 10% fetal calf serum-RPMI 1640 medium to a 
working concentration of 140 uM. JWH 015 was first diluted in 95% ethanol to a 
concentration of 10 mM and then in 10% fetal calf serum-RPMI 1640 medium to a 
working concentration of 100 uM. CB65 was first diluted in 95% ethanol to a 
concentration of 10 mM and then in 10% fetal calf serum-RPMI 1640 medium to a 
working concentration of 100 uM. SR141716A (CB1 antagonist) and SR144528 (CB2 
antagonist) were obtained from the Research Technology Branch of the National Institute 
on Drug Abuse (Rockville, MD) and were first diluted in 95% ethanol to 20 mg/ml and 
then in 10% fetal calf serum-RPMI 1640 medium to a working concentration of 20 
ug/ml.  
 
Preparation of Purified B lymphocytes 
 
Spleens were collected from C57BL/6 male and female mice at 6 to 12 weeks of  
age, and processed in a StomacherTM 80 lab blender for single cell suspensions. B cells 
were enriched by magnetic negative selection (EasySepTM from StemCell Technologies). 
Isolated B cells were cultured in six-well culture plates (Corning Life sciences, Acton, 
MA) at a concentration of 5.0 x 105cells/ml in RPMI 1640 medium supplemented with 5 
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uM 2-mercaptoethanol, 2 mM L-glutamine, 1% antibiotic/antimycotic solution (Sigma, 
St. Louis, MO), 10% heat inactivated fetal calf serum (Hyclone; Logan, UT), 0.1 - 10 
ng/ml recombinant IL-4 (BD Bioscience PharMingen, San Jose, CA, USA) and 500 
ng/ml purified hamster anti-mouse CD40 antibody (BD Bioscience PharMingen). The 
medium and reagents were replenished every 48 hrs during culture.   B cells were 
harvested after five days in culture and the purity of the cells was determined by flow-
cytometry staining using fluorochrome-conjugated monoclonal antibodies (mAbs) to 
CD19 and CD45R/B220 (BD Bioscience PharMingen). The B cell purity was greater 
than 98% as analyzed by flow Cytometry on a BD Canto II (BD Bioscience).  
 
B Cell Proliferation Assay 
 
Unstimulated, stimulated untreated (IL-4 + anti-CD40), and treated (ETOH, 
CP55940, JW015, or Methanandimide) B cells were cultured for five days and harvested 
at different time points. Cellular DNA content was measured following the protocol of 
the Cyquant NF cell proliferation assay kit (Invitrogen/Molecular Probes, Eugene, OR). 
Cellular DNA content is proportional to cell number. Cell number was calculated based 
on a standard curve. The extent of proliferation was determined by comparing cell counts 
for samples treated with drugs with untreated controls.   
 
Cell Viability 
 
 To assess cell viability, cells were cultured as previously described and stained 
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with 7-amino-actinomycin-D (7-AAD) (BD Pharmingen). Viable cells (7-AAD negative) 
and dead cells (7-AAD positive) were quantified by flow cytometry. Viable cell counts of 
whole splenocytes and B cells isolated from 6-12 weeks old C57BL/6 wildtype and CB2 
knockout mice were obtained by the trypan blue staining method.   
 
Cannabinoid Treatment of Purified B lymphocytes 
 
B cell cultures were stimulated with IL-4 (0.1 ng/ml) and anti-CD40 (500ng/ml), 
and different experimental groups were set up. Stimulated B cells were treated with the 
CB1 receptor agonist, methanandamide (0.5 or 1 uM), the CB2 receptor agonists, JWH 
015 or CB65 (0.5 or 1 uM), or the non-selective agonist, CP55940 (0.5 or 1 uM), or 
equivalent concentrations of the drug diluent, ethanol (ETOH; vehicle control). In studies 
with antagonists, B cells were pretreated with either the CB1 antagonist, SR141716A (0.1 
uM), or the CB2 antagonist, SR144528 (0.1 uM) for 15 minutes prior to CP55940 
treatment. B cells were cultured for five days followed by flow cytometry and ELISA 
analysis.  
 
Forskolin and Isobutylmethylxanthine (IBMX) Treatment of Purified B 
Lymphocytes 
 
B cells were stimulated with IL-4 (0.1-5 ng/ml) and anti-CD40 (500ng/ml) and 
treated with Forskolin or IBMX (Sigma, St. Louis, MO), 10 and 100 uM. B cells were 
cultured for five days followed by flow cytometry staining for IgE surface expression.  
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Immunoglobulins, Cell Surface Markers, and Toll like Receptors Analysis by Flow 
Cytometry 
 
To evaluate the effects of CP55940, JW015, CB65 and methanandamide on 
antibody class switching, B cell surface maker expression, and TLR 2 and 4 expression, 
treated and untreated cells were harvested after five days in culture. Prior to staining, Fc 
receptors on B cells were blocked with mouse Fc block, CD16/CD32 (BD Bioscience 
PharMingen). Cells were stained with fluorochrome-conjugated mAbs (BD Bioscience 
PharMingen) to surface immunoglobulins such as fluorescein isothiocyanate (FITC)-
conjugated anti-IgE and allophycocyanin (APC)-conjugated anti-IgM. B cell surface 
marker phenotype was assessed by flow-cytometry staining using fluorochrome-
conjugated mAbs to CD19, CD45R(B220), CD138, I-Ab (MHCII), CD80(B7-1), CD23, 
TLR2, TLR4 (BD Bioscience PharMingen). Cells were stained at 4º for 30 minutes, then 
washed in PBS containing 2% fetal calf serum and fixed in 1% paraformaldehyde.  Cells 
were acquired on a BD Canto II and analyzed by BD DIVA and Flowjo software.  
 
Intracellular CB2 Receptor Analysis by Flow Cytometry 
 
To assess the levels of CB2 protein in unstimulated and stimulated B cells, the 
cells were fluorescent stained before (day 0) and after (day 5) stimulation. Cells were 
then blocked with mouse Fc block (CD16/CD32) and normal donkey serum (NDS) 
(Chemicon International, Temecula, CA). In order to stain the intracellular CB2 receptors, 
the cells were fixed and permeabilized with cytofix/cytoperm solution (BD Bioscience) 
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to allow the antibody to enter the cell and bind the peptide mapping to the C-terminus of 
the mouse CB2 receptor. Intracellular and surface CB2 receptors were stained indirectly in 
the permeabilized cells with goat anti-mouse CB2 as primary antibody and FITC-
conjugated donkey anti-goat IgG as secondary antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA). According to the manufacturer, the anti-CB2 antibody is raised to a 15-
20 amino acid peptide within the last 50 amino acids of the C-terminus.  Cells were 
incubated for 30 minutes on ice with both antibodies, washed, and resuspended in PBS 
containing 2% fetal calf serum. Cells were acquired on a BD Calibur or BD Canto II and 
analyzed by Cellquest or Flowjo software.  
 
Mass Spectrometry Analysis of CB2 Peptide 
 
Peptide was sent to Moffitt Proteomics Facility for Mass Spectrometry (MS) 
analysis. After reverse phase peptide extraction, MS and MS/MS spectra were acquired 
from a-cyano-4-hydroxycinnamic acid matrix deposits in positive ion mode using a 
matrix assisted laser desorption ionization mass spectrometer (4700, Applied Biosystems, 
Framingham, MA). Results showed the peptide is 15 amino acids (a.a) long and is 
composed of residues 320-334 of the CB2 protein. 
 
Detection of Secreted IgE in Culture Supernatants by ELISA 
 
 To assess IgE secretion, B cells were stimulated with 0.1 ng/ml recombinant IL-4 
and 500ng/ml anti-CD40, and treated with either the CB1 receptor agonist, 
 22
methanandamide (0.5 and 1 uM), or the nonselective agonist, CP55940 (0.5 and 1 uM), 
or an equivalent concentration of drug diluent, ethanol (ETOH, vehicle control). 
Supernatants from B cell cultures were collected at five days post-treatment and the 
levels of secreted IgE in supernatants were measured using BD OptEIA kit (BD 
Bioscience PharMingen). Ninety-six-well, enzyme immunoassay plates (Corning Life 
Science), were coated with 50 ul of anti-mouse IgE (100ng/ml) in 0.1 M NaHCO3, pH 
9.5, overnight at 4°C. The wells were blocked with 150 ul of 0.5% bovine serum 
albumin/0.05% Tween 20 in PBS for 1 hr at 37ºC. B cell supernatants from cannabinoid 
treated and untreated cultures or serial dilutions of IgE standards were added and 
incubated for 2 hrs at 37ºC followed by addition of biotinylated detection antibody and 
streptavidin-horseradish peroxidase (1:250 in 50 ul) for 1 hr at 37º. The wells were 
washed between each addition. Tetramethyl benzidine (Sigma) substrate was added to the 
wells and allowed to develop at room temperature for 5-10 min. The reaction was 
stopped with 1 N sulfuric acid. Results were read at 450nm on an Emax microplate reader 
(Molecular Devices; Menlo Park, CA). The concentrations of secreted IgE were 
calculated from standard curve samples done for each plate.  
 
cAMP Detection in Forskolin and Cannabinoid Treated B Cells 
 
B cells were pre-treated with IL-4(1 ng/ml) and anti-CD40 (500ng/ml) for 48 hrs., 
harvested, counted with trypan blue in a hemacytometer, and resuspended in induction 
buffer at a concentration of 1x 106cells /500 ul. 10 ul cell suspensions were dispensed 
into each well and stimulated with either 10 ul of Forskolin (100 uM), forskolin plus 
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CP55940,  or CP55940 (0.5 and 1 uM) for 15 min. cAMP concentration was measured 
following the standard protocol from the cAMP-Glo Assay (Promega, San Luis, CA). 
Luminescence was read with a 96-well plate-reading luminometer. cAMP (nM) levels 
were calculated from Standard curve.  
 
Activation-Induced Cytidine Deaminase RT-PCR 
 
B cells were isolated as previously described, cultured for up to five days with IL-
4 (3ng/ml) and anti-CD40 (500 ng/ml), samples were harvested every 24 hrs. Total RNA 
was extracted from B cells by standard techniques using TriReagent (Sigma) and 
quantitated using RiboGreen RNA quantitation Kit (Molecular Probes, Eugene, OR). The 
extracted RNA was treated with DNase using the DNA-free kit from Ambion (Austin, 
TX).  3 ug of total RNA were used for cDNA synthesis using the avian myeloblastosis 
virus (AMV) reverse transcriptase (Promega). 2 ul of RT product were used for 
conventional PCR, which was carried out with the GoTaq DNA polymerase (Promega). 
The primer pairs used were as follows: mouse AID forward 5′-AGA TAG TGC CAC 
CTC CTG CTC ACT GG-3′ and reverse 5′-GGC TGA GGT TAG GGT TCC ATC TCA 
G-3′ (product size 209 bp) (30). Parallel PCR reactions were performed with B-actin to 
normalized cDNA concentrations. All PCR was performed in a MyCycler (BioRad) 95 
ºC 2min, 95ºC 45 s, 55ºC 2 min. 72ºC 2 min. for 30 cycles.  PCR products were separated 
on a 2% gel and photographed.  
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Statistical Analysis 
 
The standard error of the mean (SEM) was calculated for all experiments. SEM 
was estimated by taking the sample standard deviation (SD) and dividing it by the square 
root of the sample size (N).  SEM = SD/√N where SD reflects the variability of 
individual data points, and the SEM is the variability of means (67).  
 Data were analyzed by two-tailed Student’s t test. A value of  p < 0.05 was 
considered significant. 
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RESULTS 
 
Aim 1. To Determine the Extent of Cannabinoid Receptor 2 Expression in B Cell 
Activation 
 
B Cell Number 
 
Because cannabinoid receptors have been shown to play an important role in B 
cell biology, primary B cells were used as the main model to study cannabinoid effects 
and CB2 receptor expression. CB2 knockout (KO) mice are available and they have a 
phenotype similar to wildtype (WT) mice, but because we were going to be using spleen 
cells from both strains, we wanted to examine the cellularity of spleens from WT and KO 
mice. Whole splenocytes were isolated from 6-12 weeks-old WT and KO mice and B 
cells were enriched by negative selection. Whole splenocytes and B cells were stained 
with trypan blue, and live cells were counted with a hemacytometer.  As shown in figure 
1, KO  mice had a significantly lower numbers of leukocytes and B cells compared to 
WT mice, but the overall percentage of B cells in both groups was similar (approximately 
30%).   
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Figure 1. C57BL/6 WT vs. CB2 KO Cell Number. Graph shows cell counts/spleen of 
whole splenocytes and B cells isolated from C57BL/6 WT and CB2 KO mice. 6-8 weeks 
old male and female mice were used. Data represent the mean of 10 experiments ± 
S.E.M. * p<0.05, t test for WT vs. KO cell counts. 
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B Cell Purity and Viability 
 
B cell purity and viability were analyzed at different time points in culture. The 
results in Figure 2A show the scatter characteristics of primary unstimulated B cells at 
day 0 and stimulated B cells after five days in culture with IL-4 and anti-CD40. After 
enrichment, B cells were >98% CD19 positive, IgE negative, and nearly 100% viable. 
Viability studies as measured using 7-amino-actinomycin-D (7-AAD) showed that gated 
CD19 positive B cells were 98% viable at days 0 and 5.  B cell characteristics change and 
the cells get bigger and more granular as they are cultured with IL-4 and anti-CD40. At 
low concentrations of IL-4 (0.1 ng/ml), switching to surface IgE expression occur at a 
relatively low level (3%). As the concentration of IL-4 is increased (10ng/ml), IgE 
surface expression increased dramatically (97%) as shown in Figure 2B.   
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Figure 2. B Cell Purity and Viability. B cells were enriched by negative selection and 
purity was assessed by flow cytometry staining with anti-CD19-PE. Scatter graphs for 
days 0 and 5 show the populations we gated on, which are CD19+ and nearly 100% 
viable (Fig. 2A). Y-axis represents CD19+ and x-axis represents 7AAD+.  IgE surface 
expression was assessed by flow cytometry staining with anti-IgE-FITC (Fig. 2B). There 
is no IgE surface expression on unstimulated B cells, but after five days in culture, IgE 
positivity increased to 3% or 97% depending on the amounts of added IL-4 (0.1 or 10 
ng/ml). Y-axis represents CD19+ and x-axis represents IgE+. 50,000 events were analyzed 
per sample. Data are representative of 10 experiments.  
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B Cell Differentiation into Plasma Cells 
Recent reports showed that stimulation of primary B cells with IL4 and anti-CD40 
induced a significant increase in syndecam-1/CD138 positive cells associated with B cell 
differentiation into immunoglobulin secreting plasmablasts (6). CD138 (syndecam 1) is a 
proteoglycan that recognizes extracellular matrix and growth factors, appears during 
activation and differentiation of B cells, and is specific for the terminally differentiated 
plasma cell (71). Figure 3A shows scatter characteristics of primary unstimulated B cells 
at day 0 and stimulated B cells after 5 days in culture with recombinant IL-4 and anti-
CD40. The morphological characteristics change as the cells are cultured with IL-4 and 
anti-CD40 in that unstimulated cells are smaller and less granular becoming larger and 
more granular after activation.  
To further analyze cell changes, surface staining of the plasma cell marker, 
CD138, was performed on B cells from C57BL/6 WT and CB2 KO mice after activation 
with different concentrations of IL-4 (0.1 – 5 ng/ml) and  anti-CD40 (500 ng/ml) for 5 
days. Unstimulated cells have relatively low levels of CD138 (4%), however, stimulation 
with varying concentrations of IL-4 increased CD138 expression from 16 to 47%.  
Similar results were observed with B cells from CB2 KO mice (data not shown). This 
increase in CD138 expression along with the changing morphology of the cells suggests a 
transition from B cells to plasma cells in the cultures as expected in response to  
activation with IL-4 and anti-CD40 (Figure 3B).  
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Figure 3.  B Cell Differentiation into Plasma Cells. Top panel (Fig. 3A) shows IL-4 is 
a critical CD138 activator, as the concentration of Il-4 is increased in culture, there is an 
increase in CD138 surface expression. Unstimulated cells have relatively low levels of 
CD138 (4%). Stimulated cells (Day 5), at low concentrations of IL-4 (0.1 ng/ml), have 
approximately 16% CD138 expression.  As the concentration of IL-4 is increased (1, 3, 
and 5ng/ml), CD138 surface expression is also increased (47%). Bottom panel (Fig. 3B) 
shows B cell viability is not affected as the concentration of Il-4 is increased. Data is 
representative of 3 experiments.  
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B Cell Phenotype  
 
As previously described, primary cultures of mouse B cells can be induced to 
proliferate and undergo Ig class switching to IgG1 and IgE under the influence of added 
anti-CD40 antibody and recombinant IL-4 (63).  To further characterize changes 
associated with cell stimulation, cells were analyzed at different time points in culture by 
flow cytometry for the surface expression of CD19, MHCII, CD23, CD80, and CD45 
(B220).  Figure 4 shows there is no difference in surface marker expression (CD19, 
MHCII, CD80, and CD45) between day 0 and 5 except for CD23, which is decreased 
after stimulation with IL-4 and anti-CD40 for five days.   
The phenotype of unstimulated WT and CB2 KO B cells was also analyzed at 
different time points in culture. Figure 5 shows there is no difference in surface marker 
expression (CD19, CD45, CD80, MHCII, CD23) between WT and CB2 KO unstimulated 
B cells.  Their surface marker phenotypes are relatively the same. 
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Figure 4. B Cell Surface Markers. Unstimulated (day 0) and stimulated (day 5) B cells 
were stained with different surface marker antibodies raised against CD19, CD45, 
MHCII, CD80, and CD23, and analyzed by flow cytometry. Data are expressed as 
percentage (%) of gated B cells.  Gates are shown on the scatter in figure 2A. 10,000 
events were analyzed per sample. Data represent the mean of 3 experiments ± S.E.M.    
* p<0.05, t test for day 0 (unstimulated) vs. day 5 (stimulated) B cells. 
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Figure 5. B Cell Surface Markers in WT vs. CB2 KO Mice. Unstimulated (day 0) B 
cells from WT and CB2 KO mice were stained with different surface marker antibodies 
raised against CD19, CD45, MHCII, CD80, and CD23 and analyzed by flow cytometry. 
Data are expressed as percentage (%) of gated B cells.  Gates are shown on the scatter in 
figure 2A. 10,000 events were analyzed per sample.  
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CB2 Immunoreactive Protein Expression in B Cells 
 
It has been reported that CB2 receptor expression is up regulated during human 
tonsillar B cell activation through CD40 (5). Other studies indicated that the CB2 
transcript is 2 fold higher in murine B cells than in whole splenocyte preparations (36). In 
general, data from previous studies have confirmed that the expression of CB2 mRNA is 
more abundant in B cells than in other immune cell types, but because CB2 protein 
expression data in B cells is lacking, we decided to develop a method to measure this in 
purified mouse B cell populations.  CB2 receptor expression was measured on primary 
murine B cells and different B cell lines, such as K46u and 18.81. Primary B cells were 
activated with anti-CD40 and IL-4, and CB2 expression was measured at the mRNA and 
immunoreactive protein levels by RT-PCR and a newly developed flow cytometry 
technique.  
Primary B cell results showed immunoreactive protein expression was very low in 
unstimulated cells, however, the expression increased to 95% positive after stimulation 
with IL-4 and anti-CD40 for five days (Figure 6A). There was also a ten-fold difference 
in mean fluorescence intensity (MFI) per cell between unstimulated (day 0) and 
stimulated cells at day 5 (Figure 6B). The antibodies used in this study are specific for a 
CB2 peptide and therefore these results suggest that IL-4 and anti-CD40 can dramatically 
increase the expression of specific immunoreactive protein on B cells. Furthermore, B 
cell line studies have shown that CB2 levels are also abundant on two murine cell lines; a 
pre-B cell line, 18.81, and a mature B cell line, K46u (Figure 7). 
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Figure 6. CB2 Immunoreactive Protein Expression in B Cells. Unstimulated and 
stimulated B cells were stained intracellularly for CB2. Cells were collected at days 0 and 
5, blocked with Fc block and NDS, fixed with paraformaldehyde, and permeabilized with 
saponin prior to staining with primary goat anti-mouse CB2 and secondary FITC-
conjugated donkey-anti-goat IgG. Dash line histogram represents unlabeled cells, solid 
line histogram represents cells stained with secondary antibody only, and filled histogram 
represents cells stained with anti-CB2 and secondary antibody. Data are expressed as 
percentage (%) of total cells.  Lower panel shows mean fluorescence intensity (MFI) of 
CB2 positive cells of three independent experiments (Fig. 6B). Data represent the mean of 
3 experiments ± S.E.M.  * p<0.05 comparing Day 5 vs. Day 0 MFI.                         
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Figure 7. CB2 Receptor Expression in the B Cell Lines, 18.81 and K46u. Shows 
intracellular CB2 staining in B cell lines labeled with C-terminus anti-CB2. Indirect 
labeling with 1º goat- anti-mouse CB2 and 2º donkey anti-goat-FITC. Samples were 
analyzed by flow cytometry. Black histogram represents unlabeled cells, red histogram 
represents cells stain with secondary antibody only, and green histogram represents cells 
stained with anti-CB2 and secondary antibody. 10,000 events were analyzed per sample. 
Data are representative of 3 different experiments.  
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Cross-Reactivity of CB2 Antibody 
  
We were somewhat surprised at the strong immunostaining results obtained above 
(up to 95%) with the anti-CB2 peptide antibody obtained from Santa Cruz Biotechnology.  
To examine this further, we ordered the homologous specific peptide (15-20 aa) used to 
generate the antibody and set up peptide blocking experiments with anti-CB2 antibody 
and B cells.  The results in Figure 8 show that the peptide has excellent blocking potential 
showing that the antibody indeed has strong reactivity for the immunizing peptide used 
by Santa Cruz.  However, we wanted to see if this short peptide was common to other 
proteins and thus could produce cross-reacting antibodies. We sequenced the peptide by 
mass spectrometry and identified it to have the sequence YLQGLGPEGKEEGPR as 
shown in Figure 9.  This sequence was entered into an NCBI blast search resulting in a 
list of 197 proteins within the mouse genome that had sequence similarity with this 
peptide.  Some of the proteins that showed a high percentage of similarity included the 
AT-rich interactive domain-containing protein 5A (90%), immunoglobulin superfamily, 
member 8 (75%), and the opioid growth factor receptor (69%). From these results, it is 
clear that the Santa Cruz antibody could have specificity to antigenic epitopes represented 
in other mouse proteins.  
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Figure 8. CB2 Specific Peptide Blocks CB2 Antibody Binding. Graph shows 
intracellular CB2 staining in primary B cells labeled with Santa Cruz C-terminus anti-CB2 
can be completely blocked when using immunizing peptide. Samples were analyzed by 
flow cytometry. 10,000 events were analyzed per sample. Data represent the mean of 3 
experiments ± S.E.M. * p<0.05 comparing blocking peptide bar with CB2 bar.                       
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Moffitt’s National Functional Genomics Center and by the National Cancer Institute.  
 
Figure 9.  Mass Spectrometry Analysis of CB2 Peptide. After reverse phase peptide 
extraction, MS and MS/MS spectra were acquired from a-cyano-4-hydroxycinnamic acid 
matrix deposits in positive ion mode using a matrix assisted laser desorption ionization 
mass spectrometer (4700, Applied Biosystems, Framingham, MA). The peptide is 15 a.a. 
long, based on residues 320-334 of the CB2 protein. 
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CB2 Specific Immunoreactivity Increases in Stimulated B Cells 
 
We support a colony (founders from Nancy Buckley) of mice that have the C 
terminal two-thirds of the CB2 gene deleted.  Therefore, these CB2 KO mice do not 
produce CB2 protein containing the peptide sequence identified above by MS, and cells 
from these mice should therefore not show immunoreactivity with the anti-CB2 antibody 
from Santa Cruz if the antibody only reacts with CB2 protein and not cross-reacts with 
other proteins.  B cells from KO and wild type mice were stimulated with IL-4 and anti-
CD40 for 5 days and the immunoreactivity determined by flow cytometry. The results 
show (Figure 10A) that immunoreactivity increases with stimulation over time in cells 
from both groups of mice.  However, the number of % positive cells was greater in wild 
type mice than in KO mice suggesting a certain degree of CB2 specific binding in the 
wild type mice.  To estimate specific immunoreactivity, we subtracted the % reactivity 
observed in KO cells from that observed in wild type cells.  These results (Figure 10B) 
showed a steady increase in positive cells with time following stimulation suggesting that 
CB2 protein increased in B cells as they progressed through differentiation and 
maturation associated with IL-4 and anti-CD40 treatment.   
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Figure 10. CB2 Specific Immunoreactivity Increases over Time. Top panel (A) shows 
CB2 levels in B cells from wildtype and knockout mice stimulated with IL-4(3ng/ml) + 
anti-CD40(500ng/ml). Bottom panel (B) shows CB2 specific fluorescence on wildtype B 
cells after subtracting nonspecific fluorescence. Cells were collected at different time 
points, blocked with Fc block and normal donkey serum, fixed and permeabilized with 
BD Cytofix/Cytoperm solution prior to staining with primary goat, anti-mouse CB2 and 
secondary FITC-conjugated, donkey,anti-goat IgG. 10,000 events were analyzed per 
sample. Data represent the mean of 3 experiments ± S.E.M..   
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Aim 2. To Determine the Effects of Cannabinoids on B Cell Activation and 
Antibody Class Switching 
 
Effects of Cannabinoids on B Cell Proliferation and Viability  
 
Cannabinoids, independent of effects on helper T cells, may modulate antibody 
production by directly stimulating B cell proliferation and class switching in combination 
with other B cell activating factors.  Splenic B cells, from C57BL/6 CB2 wild type and 
KO, were cultured for five days with IL-4 and anti-CD-40 in the presence or absence of 
cannabinoids such as CP55,940, JWH015, CB65, and methanandamide. B cell 
proliferation was measured with CyQUANT™ NF Cell Proliferation Assay Kit.   
Before assessing cannabinoid effects on B cell proliferation, the basic system of 
unstimulated and stimulated (IL-4 + anti-CD40) B cells was analyzed.  Figure 11 shows a 
three-fold difference in proliferation between B cells treated with a low concentration of 
IL-4 (0.1 ng/ml) and those treated with a higher concentration of IL-4 (10ng/ml) after 120 
hours in culture.  These results directly show that IL-4 induces B cell proliferation, and 
the level of B cell proliferation is dependent on the IL-4 concentration.   
Unstimulated, stimulated untreated (IL-4 + anti-CD40), and stimulated drug 
treated (ETOH, CP55940, JW015, or methanandamide) B cells were cultured for five 
days and harvested at different time points. Cellular DNA content was measured 
following the protocol from the Cyquant NF cell proliferation assay kit wherein the 
cellular DNA content is proportional to the cell number. We used the minimum 
concentration of IL-4 in order to see either and increase or decrease in drug effect.  The 
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results showed that none of the 3 cannabinoid-based drugs significantly affected the 
cellular proliferation (Figure 12).  The slope of the time curves and the maximum 
proliferation responses were the same among all groups suggesting that cannabinoid 
treatment had no effect on the B cell proliferation response to IL-4.  We also wanted to 
assess the drug effects on cell viability.  For this, cells were cultured as previously 
described and stained with 7-amino-actinomycin-D (7-AAD). Viable cells (7-AAD 
negative) and dead cells (7-AAD positive) were quantitated by flow cytometry (Figure 
13).  
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Figure 11. B Cell Proliferation in response to IL-4. Cells were cultured with 0.1 (◊) or 
10 ng/ml (■) of IL-4 plus anti-CD40 (500ng/ml), then proliferation with CyQuant NF 
proliferation assay (Invitrogen) was performed at 0, 18 and 120 hrs. Data represent the 
mean of 3 experiments ± S.E.M.  * p<0.05 comparing cells treated with 0.1 vs. 10 ng/ml 
of IL-4.                         
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Figure 12.  No Effect of Cannabinoids on B Cell Proliferation. B cells were cultured 
with IL-4 (0.1ng/ml) plus anti-CD40 (500ng/ml), and treated with vehicle control, 
methanandamide or CP55940 (0.5 & 1 uM). Proliferation was measured with CyQuant 
NF proliferation assay at 0, 24, 48 and 120 hrs. y axis represents number of cells (x106) 
and x axis represents time (hrs).  Data represent the mean of 3 experiments ± S.E.M..   
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Figure 13. No Effect of Cannabinoids on B Cell Viability B cells were cultured with 
0.1 ng/ml of Il-4 plus anti-CD40 (500ng/ml) and various drugs for 5 days, then viability 
was measured by flow cytometry with 7AAD. Panel A; upper graph shows scatter and 
gating, bottom graph shows viability staining of CD19+ B cells. Panel B shows 
percentage of viable cells with and without cannabinoid treatment. Data represent the 
mean of 3 experiments ± S.E.M..   
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Effects of Cannabinoids on Surface Marker Expression 
 
To evaluate the effects of CP55940, JW015, and methanandamide on B cell 
differentiation and surface maker expression, purified B cells were stimulated for 5 days 
with IL-4 and anti-CD40 in either the presence or absence of the various cannabinoids.  
As a measure of differentiation, the B cell surface marker phenotype was assessed by 
flow-cytometry using fluorochrome-conjugated mAbs to CD19, CD45R(B220), CD138, 
I-Ab (MHCII), CD80(B7-1), and CD23.  Figure 14 shows that the purified B cells were 
highly positive for CD19, B220, and MHCII. The expression of these markers did not 
change following stimulation with IL-4 for 5 days nor did treatment with 
methanandamide or CP55940 alter the expression of these markers.  However, the 
expression of CD23 and CD138 did change.  CD23 decreased following stimulation 
while CD138 increased (Figure 15) suggesting that under the influence of IL-4 and anti-
CD40 stimulation the cells were differentiating from B cells to a more plasma cell type of 
phenotype.  CD23 is a low affinity receptor for IgE on B cells while CD138 is a common 
plasma cell marker in human and mice. Unstimulated B cells were about 80% positive for 
CD23, but after 5 days in culture, expression was significantly decreased in the control 
cultures as well as in cultures treated with methanandamide, JW015, and CB65. 
However, CP55940 treatment attenuated this drop in CD23 surface expression.  CD138 
expression increased in the IL-4 stimulated control cultures and treatment with any of the 
drugs had no effect on this increase.   
CD80 is a molecule found on activated B cells and monocytes, which provides a 
co-stimulatory signal necessary for T cell activation and survival.  Our data showed, 
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unstimulated B cells expressed low levels of CD80 and after cell activation and 
cannabinoid treatment, the CD80 surface expression increased. However, the changes 
detected were not significant (Figure 15). 
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Figure 14. Cannabinoids Have no Effect on Surface Expression of CD19, MHCII, 
and B220. B cells were stimulated with IL-4 (0.1ng/ml) and anti-CD40(500ng/ml) with 
or without drug treatment. Cells were treated with 0.5 or 1 uM CP55940 or 
Methanandamide, harvested at day five, and stained with different surface marker 
antibodies raised against CD19, MHCII, and B220. Data are expressed as percentage (%) 
of gated B cells.  Gates are shown on the scatter in figure 2A. 10,000 events were 
analyzed per sample. Data represent the mean of 3 experiments ± S.E.M..   
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Figure 15. Effects of Cannabinoids on Surface Expression of CD23, CD80, and 
CD138. B cells were stimulated with IL-4 (0.1ng/ml) and anti-CD40 (500ng/ml) with or 
without drug treatment. Cells were treated with 0.5 or 1 uM  Methanandamide, CB65, 
JW015, or CP55940, harvested at day five, and stained with different surface marker 
antibodies raised against CD23, CD80, and CD138. Data are expressed as percentage (%) 
of gated B cells.  Gates are shown on the scatter in figure 2A. 10,000 events were 
analyzed per sample. * p<0.05. Significance was only detected when comparing 
stimulated (Day 5) controls with untreated (Day 0) controls. There was no significance on 
the drug treated samples compared to day 5 and vehicle controls. Data represent the mean 
of 3 experiments ± S.E.M..   
*
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Effects of Cannabinoids on Class Switching 
 
Cannabinoids had no significant effect on B cell proliferation, viability, or surface 
marker expression. On the other hand, immunoglobulin staining data showed there was a 
decrease in IgM surface expression after the cells were stimulated with IL-4 and anti-
CD40.  Furthermore, there was a significant increased in IgE surface expression after 
stimulation and CP55940 treatment, which is a hallmark of antibody class switch 
recombination. To date, no studies have been reported on the effects of cannabinoids on 
B cell immunoglobulin class switching. Therefore, in the current study we examined the 
direct effect of the cannabinoid agonists on class switching from IgM to IgE in B cell 
cultures. B cells were stimulated in culture with IL-4 (0.1 ng/ml) and anti-CD40 
(500ng/ml), then treated with 0.5 or 1 uM CP55940 or methanandamide (Figure 16). 
Cells from the control group were untreated, and vehicle control group were treated with 
equivalent amounts of ethanol. All cells were harvested at day 5 and two-color stained 
with anti-CD19-PE and anti-IgE-FITC. CD19+ IgE+ B cells were gated and analyzed by 
flow cytometry. Only B cells treated with CP55940 (binds to both CB1 and CB2) were 
shown to have increased expression of surface IgE by day 5; treatment with 0.5 uM 
CP55940 showed a two-fold increase in surface IgE, while treatment with 1uM CP55940 
showed a three-fold increase in surface IgE. Methanandamide (selective for CB1 only) 
treated cells had very low levels of surface IgE similar to unlabeled and vehicle controls 
and in initial studies had no effect at concentrations ranging from 0.1 to 10 μM (data not 
shown). These results suggested that CB2 ligation may be more important than CB1 in 
cannabinoid-induced class switching in B cells stimulated with IL-4 and anti-CD40.   
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Besides enhancing IgE surface expression, CP55940 was also shown to enhance 
IgE secretion into culture supernatants. B cells were stimulated in culture with IL-4 and 
anti-CD40 and in presence of two different concentrations of CP55940 or 
methanandamide as described above. Untreated control cells and vehicle treated cells 
were also studied. All cells were harvested at day 5, and supernatants were collected for 
IgE analysis by ELISA (Figure 17). Cultures treated with 0.5 uM CP55940 showed a 
fifteen-fold increase in IgE levels (~5000 ng/ml) compared to vehicle control. 1 uM 
CP55940 treated cultures showed a five-fold increased in IgE levels (~2500 ng/ml) 
compare to vehicle control. Methanandamide had very little effect on IgE secretion 
similar to untreated and vehicle controls. Overall, only cultures treated with CP55940 
showed enhanced IgE secretion by day 5.   
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Figure 16. CP55940 Enhances Antibody Class Switching from IgM to IgE. B cells 
were stimulated with IL-4 (0.1ng/ml) and anti-CD40(500ng/ml) with or without drug 
treatment for 5 days. B cells were treated with 0.5 uM or 1 uM  CP55940 or 
methanandamide, cells were harvested at day five, and surface IgE levels were measured 
by flow cytometry with anti-IgE-FITC. Y-axis shows percent of gated cells, CD19+IgE+ 
B cells. Gates are shown on the scatter in figure 2A.  10,000 events were analyzed per 
sample. Data represent the mean of 8 experiments ± S.E.M..  * p<0.05 comparing 
CP55940 treated cells with vehicle controls.                         
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Figure 17.  CP55940 Enhances IgE Secretion. B cells were stimulated with IL-4 
(0.1ng/ml) and anti-CD40 (500ng/ml) with or without drug treatment for 5 days. B cells 
were treated with 0.5 or 1 uM CP55940 or methanandamide, supernatants were collected 
at day 5, and IgE secretion was measured by ELISA. Y-axis represents secreted IgE 
levels in ng/ml. Data represent the mean of 3 experiments ± S.E.M.. * p<0.05 comparing 
CP55940 treated cells with vehicle controls.                         
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Aim 3. To Determine the Molecular Mechanisms Involve in Cannabinoid 
Regulation of B Cell Antibody Class Switching 
 
CB2 Antagonist Attenuates CP55940 Effect on Surface IgE Expression 
   
The above data showed the nonselective agonist, CP55940, enhanced IgE surface 
expression and secretion in B cell cultures. On the other hand, the CB1 selective agonist, 
methanandamide, had no effect on B cell class switching. Therefore, we suspected CB2 
receptors were involved in the class switching effect observed when B cells were treated 
with CP55940. In order to confirm CB2 involvement, B cells were treated with CB1 or 
CB2 antagonists prior to CP55940 treatment. Cells were stimulated as before with IL-4 
and anti-CD40 and then pretreated with either the CB1 antagonist, SR141716A, or the 
CB2 antagonist, SR144528 (0.1 uM), for 30 min prior to CP55940 (0.5 uM) treatment. 
Controls were treated with either antagonist only.  The data showed CB2 receptor 
involvement in that pretreatment with the CB2 antagonist attenuated the CP55940 effect 
to a greater extent than pretreatment with the CB1 antagonist (Figure 18).  These data 
suggest a more robust role of CB2 in the regulation of class switching.   
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Figure 18. Treatment with Antagonists Shows CB2 Involvement. B cells were treated 
with CB1 (SR1) or CB2 (SR2) antagonist (0.1 µM) prior to CP55940 (0.5 µM) treatment 
and cultured for 5 days. Surface IgE levels were analyzed by flow cytometry with anti-
IgE-FITC. Y-axis shows percent of gated cells, CD19+IgE+ B cells. Gates are shown on 
the scatter in figure 2A.  10,000 events were analyzed per sample. Data represent the 
mean of 3 experiments ± S.E.M.. * p<0.05 comparing SR2 antagonist pretreated cells 
with CP55940 treated.  
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CP55940 Effect on IgE is Partially Inhibited in CB2 KO B cells 
 
The CP55940 effect was attenuated to a greater extent by the CB2 antagonist 
(SR2), which suggested that CB2 was mediating the class switching effect (Figure 18).  
Another way to test CB2 involvement is to use B cells from CB2 KO mice, treat with 
cannabinoids, and compare the results with those obtained in wild type B cells.  Spleens 
were collected from C57BL/6 wild type and CB2 knockout mice and B cells were 
enriched by negative selection, and cultured with IL-4 (0.1 ng/ml) and anti-CD40 
(500ng/ml), then treated with CP55940 (0.5 and 1 uM). After five days in culture, the 
cells were stained for surface IgE and analyzed by flow cytometry. The results showed 
the CP55940 effect on IgE was partially inhibited in CB2 KO B cells (Figure 19).  
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Figure 19. CP55940 Effect on IgE is Partially Inhibited in CB2 KO B cells. 
B cells from CB2 KO and wild type mice were stimulated with IL-4 (0.1ng/ml) + anti-
CD40 (500ng/ml) with or without drug treatment for 5 days. Cells were treated with 
either 0.5 or 1 uM CP55940 or methanandamide, harvested at day five, and surface IgE 
expression measured by flow cytometry with anti-IgE-FITC. * p < 0.05 for CP55940 
treated cells versus the respective vehicle (EtOH) controls. Data represent the mean of 3 
experiments ± S.E.M..  
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CP55940 Inhibits Intracellular cAMP 
 
Pretreatment with CB2 antagonist attenuated the CP55940 effect on IgE surface 
expression and CP55940 effect on IgE was partially inhibited in CB2 KO B cells. These 
results suggested a role for CB2 which is a G protein-coupled receptor.  Cannabinoid 
receptors are coupled predominantly through Gi/o proteins, negatively through the Gα 
subunit to adenylyl cyclase and positively through Gβ/γ to MAP kinase (55). It is well 
known that certain CB2 agonists are known to inhibit forskolin stimulation of cAMP (14). 
Therefore, measuring cAMP levels in B cells after forskolin and cannabinoid treatment 
can be used to determine if cannabinoids are acting through G protein-coupled 
mechanisms. To examine the direct effect of CP55940 on B cell cAMP production, cells 
were pre-treated with IL-4 and anti-CD40 for 48 hours, harvested, and stimulated with 
forskolin and/or CP55940 for 15 min. cAMP accumulation was measured by 
luminescence (Figure 20). The results showed that CP55940 treatment alone had a 
negative effect on the intracellular level of cAMP.  Furthermore, forskolin increased the 
cAMP level in B cells and this increase was attenuated in a concentration-dependent 
manner by co-treatment with CP55940.  These results suggest that CP55940 can signal 
through a Gi/o protein-coupled receptor and activate the Gαi subunit to inhibit adenylyl 
cyclase. 
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Figure 20. CP55940 Inhibits Intracellular cAMP in B cells.  Cells were pre-treated 
with IL-4(1 ng/ml) and anti-CD40 (500ng/ml) for 48 hrs, harvested, and stimulated with 
Forskolin (100 uM) and/or CP55940 (0.5, 1 uM) for 15 min. cAMP was measured by 
luminescence. Y-axis represents cAMP (nM) levels as calculated from Standard curve. 
Data represent the mean of 3 experiments ± S.E.M..  
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Forskolin and Isobutylmethylxanthine (IBMX) Inhibit IgE Surface Expression 
 
 Cannabinoids have been shown to increase surface IgE expression and secretion, 
and receptor involvement was supported by cannabinoid inhibition of cAMP levels in 
forskolin stimulated B cells.  Therefore, we tested if the effect on IgE surface 
enhancement could be affected by agents known to increase cAMP levels such as 
forskolin and phosphodiesterase inhibitors (IBMX). Forskolin activates the enzyme 
adenylyl cyclase and increases the intracellular levels of cAMP. However, IBMX is a 
phosphodiesterase inhibitor and acts by blocking the degradation of cAMP (53). In this 
experiment, B cells were cultured with a high concentration of IL-4 (5 ng/ml) to get an 
optimal IgE response, then some cells were treated with forskolin, IBMX, or both (10-
100 uM) at 0 and 48 hrs, then harvested at day five. The results showed that when B cells 
were treated with forskolin, IBMX, or both; IgE surface expression was significantly 
inhibited compared to the control group (Figure 21). 
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Figure 21. Forskolin and IBMX Inhibit IgE Surface Expression on B Cells. B cells 
were stimulated with IL-4 (5 ng/ml) and anti-CD40 (500ng/ml) and cultured for up to 5 
days. Forskolin, IBMX, or both were added at day 0.  Cells were harvested at day 5 and 
stained for surface IgE. Y-axis shows percent of gated cells, CD19+IgE+ B cells. Gates 
are shown on the scatter in figure 2A.  10,000 events were analyzed per sample. * p < 
0.05, t test for forskolin, IBMX, or both treated cells versus the control group (black bar). 
Data represent the mean of 2 experiments.  
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Forskolin Inhibits CP55940-Induced IgE Surface Expression on B Cells 
 
Our data showed the nonselective cannabinoid agonist, CP55, 940, enhanced 
surface IgE expression and secretion and inhibited forskolin stimulated cAMP 
production. This data seemed in conflict with previous reports showing that increasing 
rather than decreasing cAMP in B cells led to an increase in IgE production (9).  
Therefore, we tested if the cannabinoid effect on IgE surface enhancement could be 
affected by an agent such as forskolin that increases cAMP levels. The results showed 
that when B cells were treated with both forskolin and CP55940, IgE surface expression 
was significantly inhibited compared to the CP55940 treated controls (Figure 22).  Thus, 
it appears that in the presence of cannabinoids, a decrease in cAMP mediates an increase 
in IgE production by B cells.  These data are at variance with other reports using different 
GPCR ligands showing an opposite association between cAMP and IgE production (40). 
However, one of the relevant points in their study is the finding that p38 mitogen-
activated protein kinase (MAPK) phosphorylation and activation resulted in increased 
production of IgE. Therefore, p38 MAPK could also be an alternative mechanism of 
action for the cannabinoid effect on IgE production.  
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Figure 22. Forskolin Inhibits CP55940-Induced IgE Surface Expression on B Cells. 
B cells were stimulated with IL-4 (0.1 ng/ml) and anti-CD40 (500ng/ml) and culture for 
up to 5 days. CP55940, Forskolin, or both were added at day 0.  Cells were harvested at 
day 5 and stained for surface IgE. Y-axis shows percent of gated cells, CD19+IgE+ B 
cells. Gates are shown on the scatter in figure 2A.  10,000 events were analyzed per 
sample. * p < 0.05, t test for CP55940 and forskolin treated cells versus the CP55940 
treated controls (black bars). Data represent the mean of 3 experiments ± S.E.M..  
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Cannabinoids Enhance Toll-Like Receptor 4 Surface Expression 
 
Toll-like receptors such as TLR4 have been recently shown to mediate B cell 
activation and antibody production (58).  From studies such as these, it is now apparent 
that TLRs play a role in activating adaptive immunity as well as innate immunity.  
Because our previous studies showed cannabinoids induced IgE production in B cells 
cultures, we next examined if cannabinoids induced TLR expression on B cells.  B cells 
were stimulated with IL-4(0.1 ng/ml) and anti-CD40 (500ng/ml), then treated with 0.5 
uM or 1 uM CP55940, CB65, JW015, methanandamide, or equivalent amounts of vehicle 
control, ethanol. All cells were harvested at day 5 and two-color stained with anti-CD19-
APC and anti-TLR4-PE (Figure 23A). CD19+ TLR4+ B cells were gated and analyzed 
by flow cytometry. The results showed that stimulation with IL-4 and anti-CD40 
increased TLR4 expression by 5 days in culture, and treatment with CP55940, CB65, and 
methanandamide caused a significant increase in surface expression of TLR4 over 
control. JW015 had no significant effect on surface TLR4 possibly due to its lower 
potency for cannabinoid receptor stimulation. We also examined cannabinoid effects on 
TLR2 expression.  The results showed, that unlike TLR4, TLR2 expression was 
decreased following stimulation with IL-4 and anti-CD40 (Figure 23B), and none of the 
cannabinoids caused a change from control in expression of TLR2.  These results suggest 
that cannabinoids increase selectively TLR4 expression and not TLR2 in B cells 
stimulated with IL-4 and anti-CD40.  Furthermore, the effect was mediated by agonists 
with potency for both CB1 and CB2 suggesting both receptors are involved in the drug 
effects. 
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Figure 23. Cannabinoids Enhance Toll-Like Receptor 4 Surface Expression. B cells 
were stimulated with IL-4 (0.1ng/ml) and anti-CD40(500ng/ml) for 5 days. Then, treated 
with 0.5 uM or 1 uM CP55940, JW015, CB65, or Methanandamide. Cells were harvested 
at day five, and surface TLR4 levels were measured by flow cytometry with anti-TLR4-
PE (Figure 21A). Y-axis shows percent of gated cells, CD19+TLR4+ B cells. B cells 
were also stained with anti-TLR2-FITC (Figure 21B). Y-axis shows percent of gated 
cells, CD19+TLR2+ B cells. Gates are shown on the scatter in figure 2A.  10,000 events 
were analyzed per sample. Data represent the mean of 4 experiments ± S.E.M..  
* p<0.05, t test for cannabinoid treated samples compared to vehicle controls. 
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Both CB1 and CB2 are Involved in TLR4 Enhancement 
 
 
The previous results with selective cannabinoid receptor agonists suggested that 
both receptors were involved in the increased expression of TLR4 on B cells. In order to 
further test this, B cells were treated with CB1 or CB2 antagonist prior to treatment with 
the nonselective agonist, CP55940. All B cells were stimulated in culture with IL-4(0.1 
ng/ml) and anti-CD40 (500ng/ml). Then, B cells were treated with either the CB1 
antagonist, SR141716A, or the CB2 antagonist, SR144528, (0.1 uM) 15 min prior to 
CP55940 (0.5 -1 uM) treatment. Controls were treated with either SR1 or SR2. The 
results showed that the CP55940-induced increase in TLR4 was attenuated by both 
antagonists suggesting that both receptors were involved in the effect (Figure 24). 
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Figure 24. TLR4 Enhancement is Mediated by CB1 and CB2. B cells were treated 
with CB1 (SR1) or CB2 (SR2) antagonists (0.1 µM) prior to CP55940 (0.5 and 1 µM) 
treatment and cultured for 5 days. Surface TLR4 levels were analyzed by flow cytometry 
with anti-TLR4-PE. Y-axis shows percent of gated cells, CD19+TLR4+ B cells. Gates 
are shown on the scatter in figure 2A.  10,000 events were analyzed per sample. Data 
represent the mean of 3 experiments ± S.E.M..  
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Forskolin Inhibits CP55940-Induced TLR4 Surface Expression on B Cells 
 
  Our data showed cannabinoids enhanced surface IgE and TLR4 expression and 
inhibited forskolin-stimulated cAMP production. Therefore, we tested if the cannabinoid 
effect on TLR4 surface enhancement could be affected by an agent such as forskolin that 
increases cAMP levels as has been shown above in the case of IgE. Indeed, when B cells 
were treated with both forskolin and CP55940, TLR4 surface expression was 
significantly inhibited compared to the CP55940 treated controls (Figure 25).  Thus, it 
appears that in the presence of cannabinoids, a decrease in cAMP mediates an increase in 
TLR4 production by B cells, similar to the results observed with IgE.  
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Figure 25. Forskolin Inhibits CP55940-induced TLR4 Surface Expression on B 
Cells. B cells were stimulated with IL-4 (0.1 ng/ml) and anti-CD40 (500ng/ml) and 
culture for up to 5 days. CP55940, Forskolin, or both were added at day 0.  Cells were 
harvested at day 5 and stained for surface TLR4. Y-axis shows percent of gated cells, 
CD19+TLR4+ B cells. Gates are shown on the scatter in figure 2A.  10,000 events were 
analyzed per sample. * p < 0.05, t test for CP55940 and forskolin treated cells versus the 
CP55940 treated controls (black bars).  
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Activation-Induced Cytidine Deaminase (AID) Gene Expression Increases after B Cell 
Activation 
 
  It is well known that CSR requires at least two signals. The first is delivered by 
cytokines, such as IL-4, that induced germ-line (GL) transcription, and the second signal 
can be provided by the CD40L. The most important gene induced by these molecules is 
activation-induced cytidine deaminase (AID)(30). Our data above showed IL-4 and anti-
CD40 induced CB2 receptor activation and cannabinoids increased IgE surface 
expression and secretion. However, the genes involved in this system have not been 
investigated. Since there is plenty of evidence that activation-induced cytidine deaminase 
(AID) is required for class switch recombination (CSR)(48), we decided to examine AID 
expression after B cell activation with IL-4 (3ng/ml) and anti-CD40 (500 ng/ml).  We 
cultured the cells for up to five days and harvested samples every 24 hrs, performed RNA 
extraction and RT-PCR. Our results show an increased in AID mRNA after 48hrs in 
culture as previously reported (30). Although, the AID expression is increased in the IL-4 
and anti-CD40 system, the expression of this gene after cannabinoid treatment is yet to be 
investigated.  
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Figure 26. AID Expression in Mouse B Cells. Unstimulated (0 hr) and IL-4 (3ng/ml) 
and anti-CD40 (500 ng/ml)-stimulated cells were harvested at different time points (24-
96 hrs). Total RNA was extracted and AID transcripts were measured by RT-PCR. 
Bottom panel shows the β-actin controls.  
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DISCUSSION 
 
B Cells are Potential Targets of Cannabinoids 
 
Several in vivo and in vitro studies have shown that marijuana, synthetic, and 
endogenous cannabinoid compounds are immune modulators. They have been shown to 
modulate immune cells including B and T lymphocytes, macrophages, dendritic cells, 
and natural killer cells (32, 33). Cannabinoids such as THC have been reported to either 
suppress (27) or enhance (51) murine B cell functions such as antibody formation. In 
humans, synthetic cannabinoids such as CP55940 have been reported to enhance B cell 
proliferation (5).  However, most of these studies were done on mixed immune cell 
populations, therefore, the direct effect of cannabinoids on isolated B cells could not be 
determined. Our research study is the first to examine cannabinoid effects on purified B 
cell populations in vitro. The main findings of our project are the observations that CB2 
immunoreactivity increased over time in stimulated B cells, cannabinoids enhanced IL-4-
induced IgE production, cannabinoids enhanced TLR4 surface expression, and based on 
our findings we will discuss the possible mechanisms involved in the cannabinoid effect 
on B cell class switching and TLR4 modulation.  
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CB2 Specific Immunoreactivity Increases in Stimulated B Cells 
 
CB2 receptors are expressed more abundantly in the immune system than CB1; 
however, the role of these receptors is still not clear in both the normal functioning of the 
immune system and in the immunomodulation effect of cannabinoid-based drugs (32, 
33).  The role of these receptors in B cell biology has been of particular interest because 
B cells express the highest level of CB2 mRNA among immune cells (12), have been 
shown to be activated by cannabinoids (5), and CB2 message is increased in B cells by 
IL-4, the potent B cell activating cytokine (65). Although, several previous studies 
reported that IL-4 (65) or anti-CD40 stimulated (5, 36) B cells increased CB2 mRNA; our 
results are the first to show that B cells stimulated with both agents, IL-4 and anti-CD40, 
increased the expression of CB2 immunoreactive protein as measured by flow cytometry 
(Figure 6). 
Surprisingly, the CB2 commercially available antibody used detected very high 
protein levels (>95%), therefore, we examined the antibody specificity further by 
ordering the homologous specific peptide (15-20 aa) used to generate the antibody and 
setting up peptide blocking experiments with anti-CB2 antibody and B cells.  As 
expected, the peptide had excellent blocking potential showing that the antibody indeed 
has strong reactivity for the immunizing peptide used by Santa Cruz (Figure 8). However, 
we wanted to see if this short peptide was common to other proteins and thus could 
induce cross-reacting antibodies. We sequenced the peptide by mass spectrometry and 
identified it to have the sequence YLQGLGPEGKEEGPR as shown in Figure 9.  This 
sequence was entered into an NCBI blast search resulting in a list of 197 proteins within 
 75
the mouse genome that had sequence similarity with this peptide.  From these results, it is 
clear that the Santa Cruz antibody could have cross-reactivity to antigenic epitopes 
represented in other mouse proteins. Furthermore, results from WT and KO B cells 
showed that immunoreactivity increases with stimulation over time in cells from both 
groups of mice (Figure 10A).  However, the number of % positive cells was greater in 
WT than in KO mice suggesting a certain degree of CB2 specific binding in the WT mice.  
Therefore, the “specific” immunoreactivity was assessed by subtracting the % reactivity 
observed in KO cells from that observed in WT cells (Figure 10B).  Although this 
specific immunoreactivity conversion makes the perhaps invalid assumption that some of 
WT reactivity is CB2 specific, the conversion does support a few previous reports in other 
systems that B cell activation increases CB2 expression. 
In conclusion, these results suggest a steady increase in CB2 positive cells with 
time following stimulation, suggesting that CB2 protein increased in B cells as they 
progressed through differentiation and maturation associated with IL-4 and anti-CD40 
treatment.   
 
Cannabinoids Enhance IL-4-Induced IgE Production  
 
We are interested in cannabinoid regulation of IgE production because of the 
importance of this immunoglobulin in human disease. Cross-linking of IgE bound to Fcε 
receptors on mast cells and basophils is responsible for Type I hypersensitivity (62). 
Some of the manifestations of IgE-mediated hypersensitivity reactions include hay fever, 
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asthma, hives, food allergies, and eczema (60). Therefore, examining agents capable of 
regulating IgE production is critical for understanding disease pathogenesis and 
developing new effective therapies.  
From the previous literature, it is well understood, that primary cultures of mouse 
B cells can be induced to proliferate and undergo Ig class switching to IgG1 and IgE 
under the influence of added anti-CD40 antibody and recombinant IL-4 (63).  The IL-4 is 
the main stimulus of class switching because it induces the transcription of all germline 
genes as well as the ε germline gene leading to production of IgE (70).  Our results show 
that the degree of IgE class switching is dependent on the concentration of IL-4 added to 
the cultures and not on the concentration of anti-CD40 confirming the important role of 
this cytokine in class switching in highly purified B cell populations.  It is known that B 
cells in response to IL-4 and anti-CD40 undergo class switch recombination (CSR) 
resulting in the expression of the ε sequence in the C region of the H chain (70).   
  We are the first to examine CP55940 effects on IL-4 and anti-CD40- stimulated B 
cells and the results show that this non-selective cannabinoid agonist enhances the class 
switching event so that by 5 days in culture the drug significantly increased IgE surface 
expression and secretion (Figures 16 and 17).   CP55940 binds equally to both CB1 and 
CB2; interestingly, results with the CB1 selective agonist, methanandamide, showed no 
augmentation of class switching.  This finding coupled with our data showing the 
CP55940 effect was attenuated to a greater extent by the CB2 antagonist suggests that 
CB2 has a more prominent role in mediating the class switching effect.    
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Molecular Mechanisms Involved in the Cannabinoid Effect on IgE 
 
Gi/o Protein-Coupled Mechanisms 
 
Cannabinoid receptors are G protein-coupled receptors (GPCR) and therefore act 
through G-coupled mechanisms. CB2 is coupled predominantly through Gi/o proteins, 
i.e., negatively through the Gα subunit to adenylyl cyclase and positively through Gβ/γ to 
MAP kinase (55).  In our results, receptor involvement was supported by a concentration 
dependent inhibition of cAMP levels by cannabinoid treatment in forskolin stimulated B 
cells (Figure 20).  
The second messenger cAMP is a modulator of cellular maturation and 
differentiation possessing both inhibitory and stimulatory properties. Furthermore, agents 
that elevate intracellular cAMP levels have been shown to have immunosuppressive and 
anti-inflammatory properties (28). Cyclic nucleotides appear to play a significant role in 
the modulation of immediate hypersensitivity reactions, although their exact function is 
not well understood, it is known that substances which alter cAMP levels significantly 
alter allergic symptoms. Thus, substances that increase intracellular cAMP seem to 
relieve allergic symptoms and are used therapeutically, and agents which decrease cAMP 
have been shown to aggravate these allergic conditions(13). However, the mode of action 
and the mechanism of these effects still need to be elucidated.  
Our data showed that CP55940 enhanced surface IgE expression and secretion 
and inhibited forskolin stimulated cAMP production. These data seemed in conflict with 
previous reports that increasing rather than decreasing cAMP in B cells led to an increase 
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in IgE production (10, 62).  However, the studies showing an opposite association 
between cAMP and IgE production were done using GPCR ligands (13, 40) other than 
cannabinoids and our results demonstrate for the first time that cannabinoid ligands can 
both decrease cAMP and increase IgE in IL-4 and anti-CD40 stimulated B cells 
suggesting a more complex role of cyclic nucleotides and other GPCR mechanisms in 
IgE expression and secretion. To pursue this further, we tested if the cannabinoid effect 
on IgE surface enhancement could be affected by agents, such as forskolin and 
phosphodiesterase inhibitors (IBMX), known to increase intracellular cAMP levels. 
Indeed, when B cells were treated with forskolin and IBMX, or a combination of both, 
the IL-4 induced IgE surface expression was significantly inhibited compared to the 
control group (Figure 21). Furthermore, forskolin treatment also inhibited the 
cannabinoid effect on IgE surface expression compared to the CP55940 treated controls 
(Figure 22).  These results suggest that the CP55940 agonist is acting negatively through 
the Gα subunit to lower cAMP resulting in the activation of downstream signaling 
pathways that increase IgE surface expression.  
It is possible that cAMP and cannabinoids are acting through mechanisms 
involving Ca+2 mobilization.  For example, cAMP elevating agents suppressed IL-5 
synthesis by down-regulating the Ca2- mobilization pathway (28).  Calcium mobilization 
plays an important role in B cell activation (72) in that cell activation leads to stimulation 
of phospholipase C (PLC) with hydrolysis of phosphotidylinositol 4,5-bisphosphate 
(PIP2), generating inositol triphosphate (IP3) and diacylglycerol (DAG) (29). The IP3 
generated mobilizes calcium by binding to the IP3 receptor causing an increase in 
intracellular free calcium concentration; the DAG generated causes the activation of 
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protein kinase C (PKC), an enzyme that catalyzes the phosphorylation of several B cell 
proteins. Elevating cAMP may disrupt Ca+2 mobilization because it has been reported the 
IP3 receptor regulating Ca+2 stores is inactivated by cAMP-induced protein kinase A 
(PKA) phosphorylation leading to a reduction in the release of Ca 2+ (29).   
Besides mechanisms involving cAMP and PKA, it is also possible that 
cannabinoids are working through the modulation of other kinases such as PKC and 
MAP kinases (Figure 27).  For example, evidence supports the role of PKC in antibody 
class switching in that  PKC KO mice were not able to class switch to IgG2a/2b 
antibodies (56). Furthermore, studies have shown in CHO-transfected cells expressing 
CB2 that cannabinoid agonists activated MAP kinase and this appeared to be dependent 
on protein kinase C and independent of inhibiting adenylyl cyclase (46).  Cannabinoids, 
in addition to working through the Gα subunit and inhibiting adenylyl cyclase, also work 
through the Gβ/γ subunit inducing signaling pathways involving MAP kinase, Src, IP3K, 
and PLCβ (Figure 27) (2). In this regard, it has been shown that stimulation of CB1 and 
CB2 receptors leads to phosphorylation and activation of p42/p44 mitogen-activated 
protein kinase (MAPK), p38 MAPK and Jun N-terminal kinase (JNK) (21). Previous data 
from our own laboratory support the role of p38 kinase in the cannabinoid-induced 
modulation of dendritic cell function (unpublished).  Therefore, examining p38 MAPK, 
PKA, and CREB are crucial steps for future directions of this project.  
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Figure 27. G Protein-Coupled Mechanisms. This is a schematic representation of 
ligand-mediated activation of a G-protein-coupled receptor, which results in dissociation 
of the heterotrimeric G-protein complex and activation of downstream signaling events. 
This diagram shows the ability of Gα family members to alter adenylate cyclase (AC) 
activity. Gi activation inhibits AC activity, while the Gs activation results in the 
stimulation of AC. The βγ dimer, can also activate specific signaling pathways as well, 
including AC activity, PLCβ, and MAPK.  Adapted from reference (2).  
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Other Possible Mechanisms 
 
We know from previous literature and our own data, that B cells in response to 
IL-4 and anti-CD40 undergo class switch recombination (CSR) resulting in expression of 
the ε H chain of IgE (70).  The molecular mechanisms for CSR involve non-homologous 
recombination in the switching sites of the H chain genes as well as the up-regulation of 
the enzyme, activation-induced cytidine deaminase (AID).  There is evidence that IL-4, 
through mechanisms involving STAT6 and the cAMP response element binding (CREB), 
induces AID expression leading to IgA isotype switching (30). Since IL-4 is involved in 
CSR to both IgA and IgE, there may be also the possibility that cannabinoids are working 
through mechanisms involving STAT6, resulting in IL-4-induced AID expression and 
isotype switching. We have data showing an increased in AID message after 48hrs of B 
cell stimulation with IL-4 and anti-CD40 (Figure 26).Although, AID expression is 
increased in the IL-4 and anti-CD40 stimulated B cells, the expression of this gene after 
cannabinoid treatment is yet to be investigated.  
 
Cannabinoids Induce TLR4 Surface Expression 
 
Besides increasing the production of IgE in B cells, we also examined 
cannabinoid effects on B cell maturation and activation.  The drug effects on the 
expression of activation markers and receptors on stimulated B cells were measured by 
flow cytometry.  We found that the expression of CD19, MHC class II, B220, CD23, 
CD80, and CD138 were unaffected by cannabinoid treatment over 5 days in culture.  We 
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also examined the expression of TLRs on activated B cells in the presence of various 
cannabinoids.  TLRs are a type of pattern recognition receptors (PRR) that play a key role 
in the function of antigen-presenting cells such as dendritic cells; however, their role and 
function on lymphocytes is less clear. On dendritic cells, TLR4 is a signal-transducing 
receptor for lipopolysaccharide (LPS) (26, 57), and activation of this receptor causes the 
release of antimicrobial peptides, inflammatory cytokines and chemokines, and 
costimulatory molecules that initiate the innate immune response. TLRs also control 
multiple cell functions and activate signals that are critically involved in the initiation of 
adaptive immune responses (24) and signaling through TLR4 promotes B cell maturation 
(20) and CSR in mouse B cells (16). Furthermore, TLR4 surface expression on human B 
cells has been shown to be modulated by IL-4 (45). Therefore, TLR4 expression appears 
to be involved in adaptive immunity and B cell function.  
There is some evidence that the CB2 agonist, JWH-133, suppresses LPS-induced 
up-regulation of TLR4 and MyD88 (73), but these experiments were done in bone 
marrow derived dendritic cell cultures.  Currently, there is no literature examining the 
effect of cannabinoids on TLR expression on B cells. Our study is the first to show that 
activation of B cells with IL-4 and anti-CD40 increases TLR4 and decreases TLR2.  We 
also showed that cannabinoid treatment increased further the expression of TLR4 but had 
no effect on the level of TLR2 (Figure 23).  CP55940 increased TLR4 and is a non-
selective agonist binding equally to both CB1 and CB2; interestingly, results with the CB1 
selective agonist, methanandamide, and the CB2 selective agonist, CB65, also showed a 
significance augmentation of TLR4 surface expression.  This finding coupled with our 
data showing the cannabinoid effect was attenuated by both CB1 and CB2 antagonists 
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(Figure 24) suggests that cannabinoids are inducing TLR4 surface expression through a 
mechanism involving both CB1 and CB2. 
 
Possible Mechanism of cAMP Regulation of TLR4 Expression 
 
  Toll-like receptors such as TLR4 have been recently shown to mediate B cell 
activation and antibody production (58) and TLR4 surface expression on B cells is up-
regulated by IL-4 treatment (45). Our own data supports this upregulation by IL-4 and 
anti-CD40 and in addition shows the TLR4 expression is further increased by 
cannabinoids in a CB1 and CB2 dependent mechanism (Figure 23 and 24) but suppressed 
by Forskolin (Figure 25).    
  There are very few studies reported on the molecular mechanisms regulating 
TLR4 expression.  We speculate that a role for NFkB might be involved in our 
observations and this stems from recent data showing that stimuli known to enhance 
cAMP are capable of suppressing NF-κB (68).  In immune cells,  IgE switching requires 
induction of Cε germline transcripts which is mediated by binding of STAT-6 and NFκB 
to the Cε promoter with the expression of these factors regulated by IL-4 and CD40, 
respectively (23, 44). Also, G-protein-coupled receptors can increase NF-kB through the 
PLC and PKC pathways (50). Since in our system we see an increase in IgE and TLR4 in 
the presence of anti-CD40 and cannabinoids, and a decrease of both products by an 
increase in cAMP, we speculate that NFkB production might be involved in the 
regulation of TLR4 as well as IgE.  
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Figure 28. Possible Mechanisms Involved in Regulating Cannabinoid Effects on IgE 
and TLR4 Surface Expression. This is the proposed mechanism by which cannabinoids 
such as CP55940 are acting to upregulate B cell activation. Cannabinoids bind to G 
protein-coupled receptors, then the Gαi subunit dissociates from the Bγ and binds 
Adenylyl cyclase (AC), downregulating AC, cAMP, and Protein Kinase A. However, the 
βγ subunits can also activate PKC, MAPKs, and transcription factors, resulting in a series 
of events that promote transcriptional regulation ultimately leading to an increase in IgE 
and TLR4 surface expression. On the other side, Forskolin acts by binding directly to 
AC, increasing cAMP and resulting in a series of events that inhibit IgE and TLR4 
surface expression. Solid lines represent stimulatory signals, dash lines represent 
inhibition. 
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SUMMARY 
 
Cannabis is one of the oldest psychotropic drugs known to humanity, and it has 
been used for centuries as a remedy to alleviate different ailments(1). Recently, 
cannabinoid-based drugs have been gaining political and public support to be used for the 
treatment of chronic diseases (32). However, to date the potential risks and benefits of 
marijuana are not well understood; consequently, leading to an increased demand for 
cannabinoid research. The current study investigated the role of synthetic cannabinoids in 
the immune system and found that these drugs affect the maturation and activation of B 
lymphocytes in that these cells are induced to express more IgE and TLR4 proteins.  
Cross-linking of IgE bound to Fcε receptors on mast cell and basophils mediates the 
pathophysiology of Type I allergic diseases (62). Therefore, these studies suggest that the 
endocannabinoid system may be involved in the regulation of the allergic response and 
point the way to new strategies of controlling allergic diseases using cannabinoid-based 
drugs.  
In summary, our project contributed three main findings to the field. First, we 
showed that CB2 receptors in B cells were increased after activation with IL-4 and anti-
CD40. Then, we demonstrated that CP55940, a synthetic cannabinoid, induced IgE 
surface expression and secretion through mechanisms involving CB2 receptors. Last, we 
showed several cannabinoids were also capable of inducing TLR4 surface expression 
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through mechanisms involving cannabinoid receptors. Although the detailed mechanisms 
by which cannabinoids are mediating these responses are not well understood, G-protein-
coupled mechanisms appear to play a significant role in the modulation of B cell 
activation. Our results suggest cannabinoids negatively regulate cAMP in B cells 
resulting in increased IgE. In addition, an increase in TLR4 on activated B cells is also 
regulated by cannabinoid receptors and cAMP. Our studies presented here, show that 
cannabinoids can directly increase the maturation and differentiation of B cells in a 
substantive way in relation to mechanisms involving the role of B cells in the allergic 
response. By investigating the effect of cannabinoids on B cell activation, our results 
contribute to the understanding of the cannabinoid effects in the immune system, and 
provide new insights for future drug development in the treatment of allergic diseases.  
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